NIOX Group Plc Share Price

Equities

NIOX

GB00BJVD3B28

Pharmaceuticals

Market Closed - London S.E. 16:35:12 19/07/2024 BST 5-day change 1st Jan Change
66.6 GBX -0.60% Intraday chart for NIOX Group Plc -0.30% -0.60%

Financials

Sales 2024 * 42.48M 54.92M 4.25B Sales 2025 * 47.94M 61.98M 4.79B Capitalization 282M 365M 28.24B
Net income 2024 * 12M 15.51M 1.2B Net income 2025 * 14M 18.1M 1.4B EV / Sales 2024 * 5.99 x
Net cash position 2024 * 27.82M 35.97M 2.78B Net cash position 2025 * 36.44M 47.11M 3.64B EV / Sales 2025 * 5.13 x
P/E ratio 2024 *
24.2 x
P/E ratio 2025 *
20.7 x
Employees 92
Yield 2024 *
1.63%
Yield 2025 *
2.03%
Free-Float 50.26%
More Fundamentals * Estimated data
Dynamic Chart
1 day-0.60%
1 week-0.30%
Current month-2.92%
1 month-3.48%
3 months+3.10%
6 months+12.88%
Current year-0.60%
More quotes
1 week
66.60
Extreme 66.6
69.80
1 month
66.20
Extreme 66.2
70.00
Current year
57.20
Extreme 57.2
75.60
1 year
57.20
Extreme 57.2
75.60
3 years
29.00
Extreme 29
75.60
5 years
12.50
Extreme 12.5
75.60
10 years
12.50
Extreme 12.5
356.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 59 08/01/20
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 01/09/19
Members of the board TitleAgeSince
Chairman 71 04/12/19
Director of Finance/CFO 59 08/01/20
Director/Board Member 67 01/03/20
More insiders
Date Price Change Volume
19/07/24 66.6 -0.60% 365,656
18/07/24 67 -1.76% 243,732
17/07/24 68.2 -0.58% 94,504
16/07/24 68.6 +2.08% 315,930
15/07/24 67.2 +0.60% 143,177

Delayed Quote London S.E., July 19, 2024 at 04:35 pm

More quotes
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.666 GBP
Average target price
0.794 GBP
Spread / Average Target
+19.22%
Consensus

Annual profits - Rate of surprise